Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
ConditionHematologic Malignancy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNorthside Hospital, Inc.
About this trial
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Eligibility criteria
Qualifiers
Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells
KPS >/= 70%
Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.
Disqualifiers
Poor cardiac function (LVEF <45%)
Poor pulmonary function (FEV, FVC, DLCO <60%)
Poor liver function (bilirubin >/= 2.5mg/dL; AST or ALT >3xULN)
Poor renal function (creatinine clearance <40mL/min)
Trial design
Treatments tested in this trial
- Fludarabine
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov